| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
58,560,000 |
| Market
Cap: |
21.46(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.3664 - $0.3664 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile aTyr Pharma is a biotherapeutics company engaged in the discovery and development of medicines based on biological pathways. Co.'s primary therapeutic candidate efzofitimod, which is a fusion protein comprised of the immunomodulatory domain of histidyl-tRNA synthetase fused to the fragment crystallizable region of a human antibody. In parallel with Co.'s clinical development of efzofitimod, Co. has been improving its discovery pipeline of NRP2 antibodies and tRNA synthetases. Co.'s investigational new drug candidate ATYR2810, which is a humanized monoclonal antibody that blocks the interaction between NRP2 and one of its primary ligands, vascular endothelial growth factor.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
30,000 |
245,000 |
270,000 |
| Total Buy Value |
$0 |
$34,349 |
$514,573 |
$579,142 |
| Total People Bought |
0 |
1 |
2 |
2 |
| Total Buy Transactions |
0 |
4 |
6 |
8 |
| Total Shares Sold |
1,590 |
1,590 |
1,590 |
3,156 |
| Total Sell Value |
$2,687 |
$2,687 |
$2,687 |
$6,383 |
| Total People Sold |
1 |
1 |
1 |
1 |
| Total Sell Transactions |
1 |
1 |
1 |
2 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Schimmel Paul |
Director |
– • – |
2016-04-12 |
4 |
B |
$3.75 |
$9,682 |
D/D |
2,581 |
20,412 |
2.39 |
- |
|
| Schimmel Paul |
Director |
– • – |
2016-04-11 |
4/A |
B |
$3.45 |
$97,643 |
I/I |
27,400 |
233,581 |
2.1 |
- |
|
| Schimmel Paul |
Director |
– • – |
2016-04-11 |
4/A |
B |
$3.59 |
$18,891 |
D/D |
5,259 |
17,831 |
2.39 |
- |
|
| Schimmel Paul |
Director |
– • – |
2016-04-11 |
4 |
B |
$3.45 |
$116,535 |
D/D |
32,659 |
220,231 |
2.39 |
- |
|
| Schimmel Paul |
Director |
– • – |
2016-04-08 |
4 |
B |
$3.22 |
$273,649 |
D/D |
85,000 |
187,572 |
2.39 |
- |
|
| Schimmel Paul |
Director |
– • – |
2016-04-07 |
4 |
B |
$3.19 |
$127,584 |
D/D |
40,000 |
102,572 |
2.39 |
- |
|
| Schimmel Paul |
Director |
– • – |
2016-04-06 |
4 |
B |
$3.20 |
$80,000 |
D/D |
25,000 |
62,572 |
2.39 |
- |
|
| Mendlein John |
CEO and Director |
• • – |
2016-04-05 |
4 |
B |
$3.52 |
$8,800 |
D/D |
2,500 |
250,971 |
2.81 |
- |
|
| Mendlein John |
CEO and Director |
• • – |
2016-04-05 |
4 |
B |
$3.55 |
$8,875 |
D/D |
2,500 |
248,471 |
2.81 |
- |
|
| Schimmel Paul |
Director |
– • – |
2016-04-05 |
4 |
B |
$3.52 |
$88,118 |
D/D |
25,000 |
37,572 |
2.39 |
- |
|
| Shukla Sanjay |
Chief Medical OfficerOfficer |
• – – |
2016-03-30 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,500 |
|
- |
|
| Schimmel Paul |
Director |
– • – |
2015-09-16 |
4 |
GD |
$0.00 |
$0 |
I/I |
11,925 |
634,242 |
|
- |
|
| Clarke John K |
Former 10% Owner |
– • – |
2015-05-12 |
4 |
A |
$0.00 |
$0 |
I/I |
1,758,158 |
1,758,158 |
|
- |
|
| Clarke John K |
Former 10% Owner |
– • – |
2015-05-12 |
4 |
A |
$0.00 |
$0 |
D/D |
92,306 |
104,878 |
|
- |
|
| Mendlein John |
CEO and Executive Chairman |
• • – |
2015-05-12 |
4 |
A |
$0.00 |
$0 |
D/D |
24,055 |
245,971 |
|
- |
|
| Park John Joseph |
10% Owner |
– – • |
2015-05-12 |
4 |
A |
$0.00 |
$0 |
D/D |
1,758,158 |
1,758,158 |
|
- |
|
| Polaris Venture Partners Special Founders Fund V, |
10% Owner |
– – • |
2015-05-12 |
4 |
A |
$0.00 |
$0 |
I/I |
1,827,992 |
17,638 |
|
- |
|
| Nohra Guy P |
10% Owner |
– – • |
2015-05-12 |
4 |
A |
$0.00 |
$0 |
D/D |
1,778,064 |
1,778,064 |
|
- |
|
| Akkaraju Srinivas |
Former 10% Owner |
– • – |
2015-05-12 |
4 |
B |
$14.00 |
$4,480,000 |
I/I |
320,000 |
1,866,126 |
2.1 |
- |
|
| Akkaraju Srinivas |
Former 10% Owner |
– • – |
2015-05-12 |
4 |
A |
$0.00 |
$0 |
I/I |
1,546,126 |
1,546,126 |
|
- |
|
| Schimmel Paul |
Director |
– • – |
2015-05-12 |
4 |
A |
$0.00 |
$0 |
I/I |
547,353 |
646,167 |
|
- |
|
| Mehra Anand |
10% Owner |
– – • |
2015-05-12 |
4 |
B |
$14.00 |
$4,480,000 |
D/D |
320,000 |
1,866,126 |
2.45 |
- |
|
| Mehra Anand |
10% Owner |
– – • |
2015-05-12 |
4 |
A |
$0.00 |
$0 |
D/D |
1,546,126 |
1,546,126 |
|
- |
|
| Nashat Amir |
Former 10% Owner |
– • – |
2015-05-12 |
4 |
A |
$0.00 |
$0 |
I/I |
1,827,992 |
17,638 |
|
- |
|
| Deerfield Private Design Fund Iii, L.p. |
Possible Member of 10% Group |
– – • |
2015-05-12 |
4 |
B |
$14.00 |
$700,000 |
I/I |
50,000 |
255,764 |
1.5 |
- |
|
143 Records found
|
|
Page 5 of 6 |
|
|
